Sign In

Sangeetha Srinivasan

Director | R&D | Oncology

Sangeetha Srinivasan, Ph.D. is the Director of Pharmaceutical Research at Shasqi, a clinical-stage biotech company developing novel cancer treatments using click chemistry.13 She is involved in oncology drug development and has presented research findings at major conferences like the American Association for Cancer Research (AACR) Annual Meeting.135

At Shasqi, Srinivasan works on the company's Click Activated Protodrugs Against Cancer (CAPAC) platform, which uses Nobel Prize-winning click chemistry technology to selectively activate cancer treatments at tumor sites.4 She has presented data on SQ3370, Shasqi's lead asset, which combines a tumor-injected biopolymer with a systemically administered doxorubicin payload.1

Srinivasan has been actively involved in Shasqi's conference presentations, including at AACR, ESMO, SITC, and World ADC.3 Her work focuses on developing innovative approaches to improve cancer treatment efficacy while minimizing toxicity to healthy cells.14

Prior to her role at Shasqi, Srinivasan held positions in finance and management. She has an MBA from London Business School and completed an exchange program at the University of California, Berkeley's Haas School of Business.2

Highlights

Sangeetha Srinivasan - Parallel Advisors
Jun 1 · ascopubs.org
Phase 2a results of SQ3370, a doxorubicin-based click chemistry ...
Apr 5 · shasqi.com
Shasqi to Present Data on Novel Tumor-Targeted Drug Activation ...

Related Questions

What is Sangeetha Srinivasan's background in oncology drug development?
How does Shasqi's use of click chemistry differ from traditional cancer treatments?
What are the key findings from the AACR presentations by Shasqi?
Can you explain the significance of SQ3370 in cancer treatment?
What role does Sangeetha Srinivasan play in Shasqi's research and development?
Sangeetha Srinivasan
Sangeetha Srinivasan, photo 1
Sangeetha Srinivasan, photo 2
Add to my network

Location

United States